EUVIMED · CrossrefZeitschrift
Acta Pharmacologica Sinica
ISSN 1671-4083 · Springer Science and Business Media LLC
Neueste Artikel
Montelukast repurposed as a USP2 inhibitor induces c-Myc degradation and suppresses diffuse large B-cell lymphoma
IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Structure-based virtual screening with AlphaFold identifies CLIP1-LTK inhibitors
A natural small molecule Hdj-15 coordinates the ER and lysosomes to induce ferroptosis by targeting TrxR1
Gut microbiota-CRAMP axis controls salivary gland immune homeostasis in Sjögren’s disease
Mitochondrial antiviral signalling protein (MAVS) in cardiovascular diseases (CVD): a novel pharmacological target
Hesperetin ameliorates APAP-induced liver injury by activating a PKC–TFEB axis
Bufalin alleviates myocardial ischemia/reperfusion injury by restoring autophagic flux via the RNF216/Beclin-1 axis
Caltubin regulates microtubule stability through tubulin interaction favouring neurite regrowth
The TET2–H19 axis modulates the osteogenic differentiation of smooth muscle cells and atherosclerotic calcification
Correction: Senkyunolide A ameliorates cholestatic liver fibrosis by controlling CLCC1-mediated endoplasmic reticulum Ca2+ release
Pharmacological targeting of oncogenic condensates in cancer: mechanistic insights and therapeutic opportunities
Cell death pathways and targeting therapeutics in cancer therapy
Advances in targeted therapies for pediatric tumors
Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk
The vascular niche: an orchestrator of the spatiotemporal dynamics of distant metastasis
Epigenetic plasticity in cancer drug resistance: mechanistic insights and strategies for therapeutic intervention
Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance
Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies
Targeted protein degradation: bridging chemical biology and clinical translation
Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein–protein interaction modulators
Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination
Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress
Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions
Therapeutic cancer vaccines: development, challenges, and future perspectives
Anticancer drug discovery: Embracing the next wave of innovation
Transcription factor EB as a novel target for dimethyl fumarate to restore endothelial function in diabetes
TNF signaling at the brain-heart interface: neurovascular injury and cardiovascular vulnerability in epilepsy
EUVIMED